{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T11:41:28Z","timestamp":1777030888670,"version":"3.51.4"},"reference-count":101,"publisher":"Impact Journals, LLC","issue":"32","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,8,8]]},"DOI":"10.18632\/oncotarget.17910","type":"journal-article","created":{"date-parts":[[2017,5,17]],"date-time":"2017-05-17T10:45:17Z","timestamp":1495017917000},"page":"53751-53762","source":"Crossref","is-referenced-by-count":43,"title":["Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot?"],"prefix":"10.18632","volume":"8","author":[{"given":"Sabrina","family":"Lagniau","sequence":"first","affiliation":[{"name":"Tumor Immunology Laboratory, Department of Respiratory Medicine, Ghent University Hospital, 9000 Ghent, Belgium"},{"name":"Department of Internal Medicine, Ghent University, 9000 Ghent, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Lamote","sequence":"additional","affiliation":[{"name":"Tumor Immunology Laboratory, Department of Respiratory Medicine, Ghent University Hospital, 9000 Ghent, Belgium"},{"name":"Department of Internal Medicine, Ghent University, 9000 Ghent, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan P.","family":"van Meerbeeck","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Ghent University, 9000 Ghent, Belgium"},{"name":"Thoracic Oncology\/MOCA, Antwerp University Hospital, 2650 Edegem, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim Y.","family":"Vermaelen","sequence":"additional","affiliation":[{"name":"Tumor Immunology Laboratory, Department of Respiratory Medicine, Ghent University Hospital, 9000 Ghent, Belgium"},{"name":"Department of Internal Medicine, Ghent University, 9000 Ghent, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2017,5,17]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.critrevonc.2010.04.004","article-title":"Malignant pleural mesothelioma: the standard of care and challenges for future management","volume":"78","author":"Baas","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"2","first-page":"179","article-title":"Asbestos in developing countries: magnitude of risk and its practical implications","volume":"17","author":"Gupta","year":"2004","journal-title":"Int J Occup Med Environ Health"},{"key":"3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1183\/09059180.00007014","article-title":"Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic","volume":"24","author":"Stella","year":"2015","journal-title":"Eur Respir Rev"},{"key":"4","first-page":"260","article-title":"Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province","volume":"17","author":"Marchand","year":"1960","journal-title":"Br J Ind Med"},{"key":"5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.mrfmmm.2004.06.027","article-title":"Genotoxic effects of asbestos in humans","volume":"553","author":"Ratcliffe","year":"2004","journal-title":"Mutat Res"},{"key":"6","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1158\/1535-7163.MCT-16-0229","article-title":"Genomic Landscape of Malignant Mesotheliomas","volume":"15","author":"Kurzrock","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"7","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1634\/theoncologist.2014-0122","article-title":"Current issues in malignant pleural mesothelioma evaluation and management","volume":"19","author":"Stevenson","year":"2014","journal-title":"Oncologist"},{"key":"8","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1183\/09031936.00063109","article-title":"Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma","volume":"35","author":"Pairon","year":"2010","journal-title":"Eur Respir J"},{"key":"9","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2165\/1250444-200812060-00004","article-title":"Biomarkers for malignant pleural mesothelioma: current status","volume":"12","author":"Passioukov","year":"2008","journal-title":"Mol Diagn Ther"},{"key":"10","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1158\/1055-9965.EPI-10-0346","article-title":"Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma","volume":"19","author":"Robinson","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"11","doi-asserted-by":"publisher","first-page":"9190","DOI":"10.1074\/jbc.M312372200","article-title":"Binding of ovarian cancer antigen CA125\/MUC16 to mesothelin mediates cell adhesion","volume":"279","author":"Miyajima","year":"2004","journal-title":"J Biol Chem"},{"key":"12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3892\/ijmm_00000451","article-title":"Suppression of cell death by the secretory form of N-terminal ERC\/mesothelin","volume":"26","author":"Hino","year":"2010","journal-title":"Int J Mol Med"},{"key":"13","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1097\/JTO.0b013e3182272294","article-title":"Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma","volume":"6","author":"van Meerbeeck","year":"2011","journal-title":"J Thorac Oncol"},{"key":"14","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1200\/JCO.2011.39.6671","article-title":"Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis","volume":"30","author":"Di Serio","year":"2012","journal-title":"J Clin Oncol"},{"key":"15","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1373\/clinchem.2006.079327","article-title":"MESOMARK: a potential test for malignant pleural mesothelioma","volume":"53","author":"Sardesai","year":"2007","journal-title":"Clin Chem"},{"key":"16","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1136\/thx.2006.068114","article-title":"Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma","volume":"62","author":"Robinson","year":"2007","journal-title":"Thorax"},{"key":"17","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.athoracsur.2007.07.042","article-title":"Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions","volume":"85","author":"Allard","year":"2008","journal-title":"Ann Thorac Surg"},{"key":"18","doi-asserted-by":"publisher","first-page":"5076","DOI":"10.1158\/1078-0432.CCR-07-0629","article-title":"Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer","volume":"13","author":"Ambrosino","year":"2007","journal-title":"Clin Cancer Res"},{"key":"19","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1164\/rccm.200511-1789OC","article-title":"Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma","volume":"173","author":"Lassalle","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"20","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1515\/CCLM.2007.112","article-title":"Mesothelin family proteins and diagnosis of mesothelioma: analytical evaluation of an automated immunoassay and preliminary clinical results","volume":"45","author":"Molinini","year":"2007","journal-title":"Clin Chem Lab Med"},{"key":"21","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/01243894-200602000-00013","article-title":"Soluble mesothelin related protein in mesothelioma","volume":"1","author":"Robinson","year":"2006","journal-title":"J Thorac Oncol"},{"key":"22","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.clinbiochem.2009.03.007","article-title":"Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma","volume":"42","author":"Scherpereel","year":"2009","journal-title":"Clin Biochem"},{"key":"23","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1158\/1078-0432.CCR-06-2144","article-title":"Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment","volume":"13","author":"Lassalle","year":"2007","journal-title":"Clin Cancer Res"},{"key":"24","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1515\/CCLM.2010.066","article-title":"Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels","volume":"48","author":"Fleisher","year":"2010","journal-title":"Clin Chem Lab Med"},{"key":"25","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1097\/JTO.0b013e318187491c","article-title":"Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer","volume":"3","author":"Muley","year":"2008","journal-title":"J Thorac Oncol"},{"key":"26","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1158\/1055-9965.EPI-08-0422","article-title":"Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure","volume":"18","author":"Cebollero Rivas","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"27","first-page":"2707","article-title":"Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma","volume":"33","author":"Roncella","year":"2013","journal-title":"Anticancer Res"},{"key":"28","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1378\/chest.07-0013","article-title":"Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma","volume":"132","author":"Robinson","year":"2007","journal-title":"Chest"},{"key":"29","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1378\/chest.08-2665","article-title":"Malignant pleural mesothelioma: an update on biomarkers and treatment","volume":"136","author":"Kindler","year":"2009","journal-title":"Chest"},{"key":"30","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1164\/rccm.200907-1020OC","article-title":"Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma","volume":"181","author":"van Meerbeeck","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"31","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1097\/JTO.0b013e318180477b","article-title":"Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma","volume":"3","author":"Robinson","year":"2008","journal-title":"J Thorac Oncol"},{"key":"32","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/172460081002500307","article-title":"Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesothelioma","volume":"25","author":"Mutti","year":"2010","journal-title":"Int J Biol Markers"},{"key":"33","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1097\/JTO.0b013e31821e1c08","article-title":"Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma","volume":"6","author":"Foddis","year":"2011","journal-title":"J Thorac Oncol"},{"key":"34","first-page":"92","article-title":"Osteopontin expression and function: role in bone remodeling","author":"Noda","year":"1998","journal-title":"J Cell Biochem Suppl"},{"key":"35","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1056\/NEJMoa051185","article-title":"Asbestos exposure, pleural mesothelioma, and serum osteopontin levels","volume":"353","author":"Wali","year":"2005","journal-title":"N Engl J Med"},{"key":"36","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1155\/2013\/874212","article-title":"Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum","volume":"35","author":"Robinson","year":"2013","journal-title":"Dis Markers"},{"key":"37","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1097\/JTO.0b013e31824c9272","article-title":"CCL2, galectin-3, and SMRP combination improves the diagnosis of mesothelioma in pleural effusions","volume":"7","author":"Gregoire","year":"2012","journal-title":"J Thorac Oncol"},{"key":"38","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.ajpath.2010.12.014","article-title":"Identification of novel markers for the diagnosis of malignant pleural mesothelioma","volume":"178","author":"Gregoire","year":"2011","journal-title":"Am J Pathol"},{"key":"39","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3389\/fonc.2016.00127","article-title":"Galectin-3 Determines Tumor Cell Adaptive Strategies in Stressed Tumor Microenvironments","volume":"6","author":"Chammas","year":"2016","journal-title":"Front Oncol"},{"key":"40","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1089\/ars.2011.3978","article-title":"Is serum thioredoxin-1 a useful clinical marker for malignant pleural mesothelioma?","volume":"15","author":"Nakano","year":"2011","journal-title":"Antioxid Redox Signal"},{"key":"41","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1115050","article-title":"Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma","volume":"367","author":"Liu","year":"2012","journal-title":"N Engl J Med"},{"key":"42","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1158\/1078-0432.CCR-15-1130","article-title":"HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients","volume":"22","author":"Yang","year":"2016","journal-title":"Clin Cancer Res"},{"key":"43","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1136\/thoraxjnl-2014-205205","article-title":"Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma","volume":"69","author":"Robinson","year":"2014","journal-title":"Thorax"},{"key":"44","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00408-016-9868-1","article-title":"Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure","volume":"194","author":"Senyigit","year":"2016","journal-title":"Lung"},{"key":"45","doi-asserted-by":"publisher","first-page":"12611","DOI":"10.1073\/pnas.1006542107","article-title":"Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation","volume":"107","author":"Carbone","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"46","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1056\/NEJMc1213514","article-title":"Fibulin-3 as a biomarker for pleural mesothelioma","volume":"368","author":"van Meerbeeck","year":"2013","journal-title":"N Engl J Med"},{"key":"47","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1385\/1-59745-123-1:33","article-title":"MicroRNA biogenesis: isolation and characterization of the microprocessor complex","volume":"342","author":"Shiekhattar","year":"2006","journal-title":"Methods Mol Biol"},{"key":"48","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1097\/JTO.0b013e31820db125","article-title":"MicroRNAs dysregulation in human malignant pleural mesothelioma","volume":"6","author":"Tognon","year":"2011","journal-title":"J Thorac Oncol"},{"key":"49","doi-asserted-by":"publisher","first-page":"771","DOI":"10.2353\/jmoldx.2010.090169","article-title":"A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma","volume":"12","author":"Goren","year":"2010","journal-title":"J Mol Diagn"},{"key":"50","doi-asserted-by":"publisher","first-page":"635748","DOI":"10.1155\/2015\/635748","article-title":"MicroRNA and mRNA features of malignant pleural mesothelioma and benign asbestos-related pleural effusion","volume":"2015","author":"Thomas","year":"2015","journal-title":"Biomed Res Int"},{"key":"51","doi-asserted-by":"publisher","first-page":"82700","DOI":"10.18632\/oncotarget.12408","article-title":"Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers","volume":"7","author":"Bovenzi","year":"2016","journal-title":"Oncotarget"},{"key":"52","doi-asserted-by":"publisher","first-page":"703","DOI":"10.4161\/rna.20481","article-title":"The hallmarks of cancer: a long non-coding RNA point of view","volume":"9","author":"Diederichs","year":"2012","journal-title":"RNA Biol"},{"key":"53","doi-asserted-by":"publisher","first-page":"e70940","DOI":"10.1371\/journal.pone.0070940","article-title":"Long non coding RNAs (lncRNAs) are dysregulated in Malignant Pleural Mesothelioma (MPM)","volume":"8","author":"Reid","year":"2013","journal-title":"PLoS One"},{"key":"54","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1378\/chest.14-0781","article-title":"Breathomics in lung disease","volume":"147","author":"Sterk","year":"2015","journal-title":"Chest"},{"key":"55","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1158\/1055-9965.EPI-13-0737","article-title":"Strengths, weaknesses, and opportunities of diagnostic breathomics in pleural mesothelioma-a hypothesis","volume":"23","author":"van Meerbeeck","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"56","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/10408340600976499","article-title":"Current status of methods and techniques for breath analysis","volume":"37","author":"Duan","year":"2007","journal-title":"Critical Reviews in Analytical Chemistry"},{"key":"57","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/mas.20033","article-title":"Selected ion flow tube mass spectrometry (SIFT-MS) for on-line trace gas analysis","volume":"24","author":"Spanel","year":"2005","journal-title":"Mass Spectrom Rev"},{"key":"58","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/mas.20303","article-title":"Progress in SIFT-MS: breath analysis and other applications","volume":"30","author":"Smith","year":"2011","journal-title":"Mass Spectrom Rev"},{"key":"59","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1373\/clinchem.2015.238840","article-title":"Ion Mobility in Clinical Analysis: Current Progress and Future Perspectives","volume":"62","author":"Yost","year":"2016","journal-title":"Clin Chem"},{"key":"60","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.tibtech.2016.08.005","article-title":"Artificial Nose Technology: Status and Prospects in Diagnostics","volume":"35","author":"Fenniri","year":"2017","journal-title":"Trends Biotechnol"},{"key":"61","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.lungcan.2011.08.009.62","article-title":"An electronic nose distinguishes exhaled breath of patients with Malignant Pleural Mesothelioma from controls","volume":"75","author":"Sterk","year":"2012","journal-title":"Lung Cancer"},{"key":"62","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1183\/09031936.00040911","article-title":"A breath test for malignant mesothelioma using an electronic nose","volume":"40","author":"Yates","year":"2012","journal-title":"Eur Respir J"},{"key":"63","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1007\/s00216-010-4238-y","article-title":"Chemical characterization of exhaled breath to differentiate between patients with malignant plueral mesothelioma from subjects with similar professional asbestos exposure","volume":"398","author":"Tutino","year":"2010","journal-title":"Anal Bioanal Chem"},{"key":"64","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s12127-014-0147-7","article-title":"Signals in asbestos related diseases in human breath - preliminary results","volume":"17","author":"Kraus","year":"2014","journal-title":"Int J Ion Mobil Spectrom"},{"key":"65","doi-asserted-by":"publisher","first-page":"046001","DOI":"10.1088\/1752-7155\/10\/4\/046001","article-title":"Detection of malignant pleural mesothelioma in exhaled breath by multicapillary column\/ion mobility spectrometry (MCC\/IMS)","volume":"10","author":"van Meerbeeck","year":"2016","journal-title":"J Breath Res"},{"key":"66","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.otohns.2007.02.005","article-title":"In vitro discrimination of tumor cell lines with an electronic nose","volume":"137","author":"Hanson","year":"2007","journal-title":"Otolaryngol Head Neck Surg"},{"key":"67","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1158\/1055-9965.EPI-09-0162","article-title":"TD-GC-MS analysis of volatile metabolites of human lung cancer and normal cells in vitro","volume":"19","author":"Troppmair","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"68","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1039\/c2an36185j","article-title":"Quantification by SIFT-MS of acetaldehyde released by lung cells in a 3D model","volume":"138","author":"Sule-Suso","year":"2013","journal-title":"Analyst"},{"key":"69","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1039\/b916158a","article-title":"Quantification of acetaldehyde and carbon dioxide in the headspace of malignant and non-malignant lung cellsby SIFT-MS","volume":"134","author":"Smith","year":"2009","journal-title":"Analyst"},{"key":"70","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1475-2867-12-7","article-title":"Analysis of volatile organic compounds released from human lung cancer cells and from the urine of tumor-bearing mice","volume":"12","author":"Beauchamp","year":"2012","journal-title":"Cancer Cell Int"},{"key":"71","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1016\/S0140-6736(98)07552-7","article-title":"Volatile organic compounds in breath as markers of lung cancer: a cross-sectional study","volume":"353","author":"McVay","year":"1999","journal-title":"Lancet"},{"key":"72","doi-asserted-by":"publisher","first-page":"016013","DOI":"10.1088\/1752-7163\/aa5cc5","article-title":"Factors that influence the volatile organic compound content in human breath","volume":"11","author":"van Schooten","year":"2017","journal-title":"J Breath Res"},{"key":"73","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/cbic.201200011","article-title":"Characterization of volatile organic compounds in human leukocyte antigen heterologous expression systems: a cell\u2019s \u201cchemical odor fingerprint\u201d","volume":"13","author":"Davis","year":"2012","journal-title":"Chembiochem"},{"key":"74","first-page":"09","article-title":"Biomarkers: An Emerging Tool for Diagnosis of a Disease and Drug Development","volume":"1","author":"Chatterjee","year":"2011","journal-title":"Asian J Res Pharm Sci"},{"key":"75","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3978\/j.issn.2218-676X.2015.06.04","article-title":"Cancer biomarker discovery and validation","volume":"4","author":"Hoshida","year":"2015","journal-title":"Transl Cancer Res"},{"key":"76","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.molonc.2012.01.010","article-title":"Cancer biomarkers","volume":"6","author":"Hayes","year":"2012","journal-title":"Mol Oncol"},{"key":"77","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.molmed.2015.08.001","article-title":"Exhaled Molecular Fingerprinting in Diagnosis and Monitoring: Validating Volatile Promises","volume":"21","author":"Sterk","year":"2015","journal-title":"Trends Mol Med"},{"key":"78","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1093\/jnci\/93.14.1054","article-title":"Phases of biomarker development for early detection of cancer","volume":"93","author":"Yasui","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"79","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jchromb.2015.10.004","article-title":"Investigation of cell culture volatilomes using solid phase micro extraction: Options and pitfalls exemplified with adenocarcinoma cell lines","volume":"1006","author":"Nehls","year":"2015","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"80","first-page":"59","article-title":"[Volatile hydrocarbons in exhaled air: preliminary data on the characteristic profile associated with lung tumors]. [Article in Italian]","volume":"25","author":"Mutti","year":"2003","journal-title":"G Ital Med Lav Ergon"},{"key":"81","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1515\/CCLM.2009.133","article-title":"Determination of volatile organic compounds in exhaled breath of patients with lung cancer using solid phase microextraction and gas chromatography mass spectrometry","volume":"47","author":"Hackl","year":"2009","journal-title":"Clin Chem Lab Med"},{"key":"82","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1378\/chest.123.6.2115","article-title":"Detection of lung cancer with volatile markers in the breath","volume":"123","author":"Rom","year":"2003","journal-title":"Chest"},{"key":"83","doi-asserted-by":"publisher","first-page":"027111","DOI":"10.1088\/1752-7155\/8\/2\/027111","article-title":"Comparative analyses of volatile organic compounds (VOCs) from patients, tumors and transformed cell lines for the validation of lung cancer-derived breath markers","volume":"8","author":"Amann","year":"2014","journal-title":"J Breath Res"},{"key":"84","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1002\/cncr.22844","article-title":"A study of the volatile organic compounds exhaled by lung cancer cellsfor breath diagnosis","volume":"110","author":"Zhang","year":"2007","journal-title":"Cancer"},{"key":"85","first-page":"278","article-title":"[Determination of volatile organic compounds in lung cancer cell lines and lung cancer tissue]. [Article in Chinese]","volume":"39","author":"Wang","year":"2010","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"key":"86","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1186\/1471-2407-9-348","article-title":"Noninvasive detection of lung cancer by analysis of exhaled breath","volume":"9","author":"Lukas","year":"2009","journal-title":"BMC Cancer"},{"key":"87","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3233\/CBM-2012-00270","article-title":"The analysis of volatile organic compounds biomarkers for lung cancer in exhaled breath, tissues and cell lines","volume":"11","author":"Ying","year":"2012","journal-title":"Cancer Biomark"},{"key":"88","first-page":"419","article-title":"Release of volatile organic compounds from the lung cancer cell line NCI-H2087 in vitro","volume":"29","author":"Troppmair","year":"2009","journal-title":"Anticancer Res"},{"key":"89","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1475-2867-8-17","article-title":"Release of volatile organic compounds (VOCs) from the lung cancer cell line CALU-1 in vitro","volume":"8","author":"Troppmair","year":"2008","journal-title":"Cancer Cell Int"},{"key":"90","doi-asserted-by":"publisher","first-page":"046008","DOI":"10.1088\/1752-7155\/5\/4\/046008","article-title":"The application of statistical methods using VOCs to identify patients with lung cancer","volume":"5","author":"Buszewski","year":"2011","journal-title":"J Breath Res"},{"key":"91","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00216-012-6102-8","article-title":"Identification of volatile lung cancer markers by gas chromatography-mass spectrometry: comparison with discrimination by canines","volume":"404","author":"Rudnicka","year":"2012","journal-title":"Anal Bioanal Chem"},{"key":"92","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1515\/CCLM.2011.769","article-title":"Investigation of lung cancer biomarkers by hyphenated separation techniques and chemometrics","volume":"50","author":"Cieslinski","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"93","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.lungcan.2015.07.005","article-title":"Breath carbonyl compounds as biomarkers of lung cancer","volume":"90","author":"Fu","year":"2015","journal-title":"Lung Cancer"},{"key":"94","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jchromb.2004.09.007","article-title":"Development of headspace solid-phase microextraction with on-fiber derivatization for determination of hexanal and heptanal in human blood","volume":"813","author":"Zhang","year":"2004","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"95","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1016\/j.jchromb.2010.01.022","article-title":"Determination of aldehydes in exhaled breath of patients with lung cancer by means of on-fiber-derivatisation SPME-GC\/MS","volume":"878","author":"Mutti","year":"2010","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"96","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1002\/ijc.24970","article-title":"Breath gas aldehydes as biomarkers of lung cancer","volume":"126","author":"Miekisch","year":"2010","journal-title":"Int J Cancer"},{"key":"97","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.jtcvs.2014.06.006","article-title":"Quantitative analysis of exhaled carbonyl compounds distinguishes benign from malignant pulmonary disease","volume":"148","author":"Fu","year":"2014","journal-title":"J Thorac Cardiovasc Surg"},{"key":"98","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/cam4.162","article-title":"Noninvasive detection of lung cancer using exhaled breath","volume":"3","author":"Bousamra","year":"2014","journal-title":"Cancer Med"},{"key":"99","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/j.jtcvs.2015.08.092","article-title":"High sensitivity for lung cancer detection using analysis of exhaled carbonyl compounds","volume":"150","author":"Bousamra","year":"2015","journal-title":"J Thorac Cardiovasc Surg"},{"key":"100","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3233\/CBM-2010-0182","article-title":"Analysis of volatile organic compounds (VOCs) in the headspace of NCI-H1666 lung cancer cells","volume":"7","author":"Troppmair","year":"2010","journal-title":"Cancer Biomark"},{"key":"101","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1016\/j.jchromb.2011.09.001","article-title":"Determination of volatile organic compounds as biomarkers of lung cancer by SPME-GC-TOF\/MS and chemometrics","volume":"879","author":"Buszewski","year":"2011","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.17910","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T21:20:24Z","timestamp":1589145624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.17910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,17]]},"references-count":101,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2017,8,8]]}},"alternative-id":["17910","28881848"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.17910","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,17]]}}}